Cannabis Retailer High Tide Achieves Record Revenue, EBITDA For Second Consecutive Quarter

March 18, 2023 · UK.Investing.com

Cannabis retailer High Tide Inc. (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA) released first-quarter results Friday, posting a 64% year-over-year revenue increase.

“Our Q1 earnings numbers represent the best quarter ever in High Tide’s history in terms of revenue, adjusted EBITDA, and market share growth. Q1 is now our second consecutive quarter of record revenue and adjusted EBITDA and saw a meaningful improvement in our free cash flow position,” said CEO Raj Grover.

HITI Financial Highlights

  • Revenue increased to $118.1 million in the first fiscal quarter of 2023 compared to $72.2 million during the same period in 2022, representing an increase of 64% year-over-year and 9% sequentially.
  • Gross profit increased to $32.2 million in the first fiscal quarter of 2023 compared to $23 million during the same period in 2022, representing an increase of 40% year-over-year and 9% sequentially.
  • The gross profit margin in the three months ended Jan. 31, 2023, was 27%, consistent with the previous three quarters. Gross margins earned in High Tide’s brick-and-mortar stores ticked higher sequentiallym the company said.
  • Adjusted EBITDA increased to $5.5 million in the first fiscal quarter of 2023 compared to $3 million during the same period in 2022, representing an increase of 86% year-over-year and 10% sequentially, per the news release.

The company has achieved its 12th consecutive quarter of positive adjusted EBITDA, Grover said, with a fourth consecutive quarter of sequential same-store sales growth, indicating its strength in the market.

The company represents 9% of the Canadian cannabis retail market outside of Quebec, as reported exclusively by Benzinga.

In the first fiscal quarter of 2023, salaries, wages and benefits accounted for 12% of revenue, an improvement from 14% in the same quarter of the previous year and consistent with the previous three quarters.

General and administrative expenses represented 6% of revenue in Q1 2023, an improvement from 8% in Q1 2022 and 7% in the previous quarter, indicating strong cost controls by the company. The sales of Cabanalytics data totaled $6.6 million in Q1 2023, an increase from $4.7 million in the same period last year, with a 3% sequential increase.

During the first fiscal quarter of 2023, same-store sales increased by 52% compared to the same period in 2022, with a sequential increase of 4%, marking six consecutive quarters of same-store sales growth.

The company also reported a 58% increase in the ELITE cannabis paid loyalty program membership, reaching about 9,500 members. As of Jan. 31, the company had $23.7 million in cash on hand.

“We are also pleased to share a shift in our strategy to ensure long-term growth and sustainability, with a goal of becoming free cash flow positive by the end of this calendar year. In contrast with much of the cannabis industry, we’ve remained focused on continuing to strengthen our operations and set attainable growth goals. While we are not abandoning growth through M+A in the medium and long-term, our short-term focus has shifted to attaining free cash flow profitability in the coming months,” said Grover.

High Tide aims to become free cash flow positive within this calendar year and remains the highest revenue-generating cannabis company reporting in Canadian dollars. The company has 151 locations, over 975,000 Cabana Club members and a global customer database of over 4.5 million, making it the largest non-franchised cannabis retailer in Canada.

Come meet Grover in person as well as other fascinating leaders in the cannabis industry at the Benzinga Cannabis Capital Conference at Miami Beach’s historic Fontainebleau Hotel in Florida on April 11-12. This is the place to get DEALS DONE, raise money, jumpstart M&A, and meet investors and key partners. Secure your tickets now before prices go up. (Full Story)

In categories:Finance International
Tags:
Next Post

Canadian cannabis industry reckons with inflated THC label claims

Potency testing on store-bought cannabis flower by a Canadian laboratory has found THC levels significantly lower than the labeled value, sparking an industrywide conversation about how to address inaccurate THC claims. Rob O’Brien, CEO and chief science officer of Kelowna, British Columbia-based…
Read
Previous Post

Germany To Introduce Bill To Legalize Cannabis In The Coming Weeks

Germany is moving forward with its plan to legalize cannabis for recreational use, aiming to become the first European country to regulate the sale of cannabis products. But while supranational legal frameworks may pose obstacles to legalization, Lauterbach has received…
Read
Random Post

Maryland-based cannabis retailer buoys business with spa and holistic pharmacy

Executives often undertake business diversification as a hedge against their core business or the economy going sour. But in 2014, when Curio Wellness co-founder and Chief Brand Officer Wendy Bronfein and her partners conceived the idea for a Timonium, Maryland-based…
Read
Random Post

Delta-8 THC, HHC, THCP are Legal, Now Illegal, Now Legal, Again - Arkansas Judge Opens Flood Gates for Hemp Derived THC Products

A recent ruling by a federal judge has raised questions within the industry: Has this judge effectively legalized hemp-derived cannabinoids such as HHC, Delta-8 THC, THCa, and THCP flower? In summary, the judge in Arkansas determined that the 2018 Farm Bill holds greater legal authority than a…
Read
Random Post

Canadian cannabis companies back off from US hemp CBD market

Back in the regulated marijuana industry’s more heady days, a U.S. hemp-derived CBD subsidiary seemed like the must-have accessory for any Canadian cannabis company worth its bud. Canopy Growth Corp. owned a hemp farm in Springfield, New York, and planned…
Read
Random Post

DEA Official Says New Rules Are Coming For Synthetic Cannabinoids, Including CBD And Delta-8 THC

The Drug Enforcement Administration (DEA) will soon be proposing new rules to clarify that synthetically manufactured cannabinoids like delta-8 THC are prohibited controlled substances. At the agency’s 2023 Supply Chain Conference earlier this month, Terrance Boos, chief of DEA’s Drug…
Read